Abstract
We isolated pure, viable populations of tumor-cytolytic T cells directly from patient blood samples using flow cytometric quantification of the surface mobilization of CD107a—an integral membrane protein in cytolytic granules—as a marker for degranulation after tumor stimulation. We show that tumor-cytolytic T cells are indeed elicited in patients after cancer vaccination, and that tumor reactivity is strongly correlated with efficient T-cell recognition of peptide-bearing targets. We combined CD107a mobilization with peptide–major histocompatibility complex (P-MHC) tetramer staining to directly correlate antigen specificity and cytolytic ability on a single-cell level. This showed that tumor-cytolytic T cells with high recognition efficiency represent only a minority of peptide-specific T cells elicited in patients after heteroclitic peptide vaccination. We were also able to expand these cells to high numbers ex vivo while maintaining their cytolytic potential. These techniques will be useful not only for immune monitoring of cancer vaccine trials, but also for adoptive cellular immunotherapy after ex vivo expansion. The ability to rapidly identify and isolate tumor-cytolytic T cells would be very useful in cancer immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96 (1996).
Lee, P.P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677–685 (1999).
Lee, P. et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836–3847 (2001).
Weber, J. et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97, 186–200 (2003).
Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99, 16168–16173 (2002).
Molldrem, J.J. et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111, 639–647 (2003).
Oh, S. et al. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 170, 2523–2530 (2003).
Dutoit, V. et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168, 1167–1171 (2002).
Echchakir, H. et al. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl. Acad. Sci. USA 99, 9358–9363 (2002).
O'Connor, D.H. et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8, 493–499 (2002).
Cawthon, A.G. & Alexander-Miller, M.A. Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J. Immunol. 169, 3492–3498 (2002).
Slifka, M.K. & Whitton, J.L. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat. Immunol. 2, 711–717 (2001).
Margulies, D.H. TCR avidity: it's not how strong you make it, it's how you make it strong. Nat. Immunol. 2, 669–670 (2001).
Yee, C., Savage, P.A., Lee, P.P., Davis, M.M. & Greenberg, P.D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 2227–2234 (1999).
Crawford, F., Kozono, H., White, J., Marrack, P. & Kappler, J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8, 675–682 (1998).
Derby, M.A., Wang, J., Margulies, D.H. & Berzofsky, J.A. Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int. Immunol. 13, 817–824 (2001).
Dutoit, V., Guillaume, P., Cerottini, J.C., Romero, P. & Valmori, D. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. Eur. J. Immunol. 32, 3285–3293 (2002).
Betts, M. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods (in the press).
Whiteside, T.L. et al. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9, 641–649 (2003).
Snyder, J.E. et al. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat. Med. 9, 231–236 (2003).
Tomaru, U. et al. Detection of virus-specific T cells and CD8(+) T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat. Med. 9, 469–476 (2003).
Lim, D.G., Bieganowska Bourcier, K., Freeman, G.J. & Hafler, D.A. Examination of CD8+ T cell function in humans using MHC class I tetramers: similar cytotoxicity but variable proliferation and cytokine production among different clonal CD8+ T cells specific to a single viral epitope. J. Immunol. 165, 6214–6220 (2000).
Bachmann, M.F., Barner, M., Viola, A. & Kopf, M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur. J. Immunol. 29, 291–299 (1999).
Dudley, M.E. et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243–251 (2002).
Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat. Immunol. 3, 999–1005 (2002).
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. & Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
Acknowledgements
This work was supported by National Institutes of Health grant R01 CA 090809 (P.L.) and the Damon Runyon Cancer Research Foundation Scholar Award (P.L.). We thank J. Harvell for immunohistochemical staining of melanoma cell lines, C. Yee for kindly providing the mel526 cell line, J. Yu for antibody conjugation and A. Salles and M. Mallipeddi for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Rubio, V., Stuge, T., Singh, N. et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9, 1377–1382 (2003). https://doi.org/10.1038/nm942
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm942
This article is cited by
-
PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma
Cancer Immunology, Immunotherapy (2024)
-
Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression
Nature Communications (2022)
-
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
npj Breast Cancer (2021)
-
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Nature Communications (2021)
-
CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus
Signal Transduction and Targeted Therapy (2020)